Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 2 Phase 2 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Neoplasms 3 Fallopian Tube Neoplasms 3 Breast Neoplasms 3 Small Cell Lung Carcinoma 2 Prostatic Neoplasms 2 Carcinoma, Squamous Cell 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Pancreatic Adenocarcinoma 1 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Lung Neoplasms 1 Laryngeal Diseases 1 Glioma 1 Carcinoma, Transitional Cell 1 Carcinoma 1 Anus Neoplasms 1 Advanced Solid Tumor, Adult 1 Advanced Solid Tumor 1

Interventions

Temozolomide 26 Radiotherapy 10 Bevacizumab 10 Carboplatin 6 Irinotecan 5 pembrolizumab 4 Radiation 4 Nivolumab 4 IL13-PE38 4 temsirolimus 3 Surgical Procedures, Operative 3 Magnetic Resonance Spectroscopy 3 Immunotherapy, Adoptive 3 Erlotinib Hydrochloride 3 Aminolevulinic Acid 3 trametinib 2 olaparib 2 lutetium Lu 177 dotatate 2 fludarabine 2 dabrafenib 2 cemiplimab 2 abemaciclib 2 Vorinostat 2 Transurethral Resection of Bladder 2 Sirolimus 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 Imatinib Mesylate 2 Flucytosine 2 Cyclophosphamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioma × niraparib × Clear all

NCT06258018 2024-08-30

ONC-2022-001

Istituto Clinico Humanitas

Phase 1/2 Not yet recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡